Cancer Immunology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 78545
Special Issue Editors
Interests: colorectal cancer; tumor immunology; T cells; immune cells; microbiome
Special Issues, Collections and Topics in MDPI journals
Interests: gastrointestinal cancers; cancer immunology; immune checkpoint inhibitors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer immunotherapies have revolutionized the treatment of various cancer types, yet a substantial proportion of patients are resistant to immunotherapies. Over the past two decades, studies have made it clear that communication between cancer cells and the immune system is a dynamic process. Comprehensive genomic analysis of samples from recent clinical trials and pre-clinical investigations in mouse models of cancer have provided insights into how tumors evade immunotherapies and host antitumor immune response. In this Special Issue, we welcome articles highlighting the current status of cancer immunotherapies and aspects of adoptive and acquired immunotherapy resistance, immune cell functions in the tumor microenvironment, and tumor–immune cell interactions. We will also cover current and future management of immunotherapies resistance, and consider crucial questions remaining in this field.
Dr. Subbaya Subramanian
Dr. Xianda Zhao
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor immunology
- cancer immunology
- immunotherapies
- immune cells
- resistance
- cancers
- immunotherapy resistance
- immune checkpoint genes